Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Guideline (EuroGuiDerm) on atopic eczema: Living update.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Determinants of costs and benefits in atopic dermatitis routine care in Germany.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same journal

Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A, Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma.

Allergy·2026
Same journal

Surgical Management of Non-Allergic Rhinitis-An EAACI Task Force Position Paper.

Allergy·2026
Same journal

Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions.

Allergy·2026
Same journal

EAACI Guidelines on Environmental Science for Allergy and Asthma-Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy.

Allergy·2026
Same journal

Diet-Microbiome-Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications.

Allergy·2026
Same journal

Melittin in AllergoOncology: From Honey Bee Venom to Anti-Cancer Therapeutic Innovation-An EAACI Position Paper.

Allergy·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Atopic dermatitis: a candidate for disease-modifying strategy.

T Bieber1, M Cork, S Reitamo

  • 1Department of Dermatology and Allergy, University of Bonn, Bonn, Germany. thomas.bieber@ukb.uni-bonn.de

Allergy
|June 8, 2012
PubMed
Summary
This summary is machine-generated.

Disease modification aims to alter chronic diseases using biomarkers for patient stratification. Research into atopic dermatitis (AD) biomarkers and disease-modifying strategies is crucial for managing AD and preventing allergic asthma.

More Related Videos

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology
12:34

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Related Experiment Videos

Last Updated: May 21, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology
12:34

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

Published on: January 12, 2024

Area of Science:

  • Immunology
  • Genetics
  • Dermatology

Background:

  • Chronic diseases require strategies to alter their natural course.
  • Biomarker-based patient stratification is key for targeted therapies.
  • Atopic dermatitis (AD) has a complex genetic background and natural history.

Purpose of the Study:

  • To emphasize the need for biomarker research in atopic dermatitis (AD).
  • To explore the potential for developing disease-modifying strategies for AD.
  • To address the link between AD, its genetic factors, and the development of allergic asthma.

Main Methods:

  • Literature review on disease modification concepts.
  • Analysis of current understanding of AD genetics and natural history.
  • Discussion of biomarker applications in AD patient stratification.

Main Results:

  • Disease modification offers a paradigm shift in managing chronic conditions.
  • Biomarkers are essential for identifying patient subgroups for targeted interventions.
  • Understanding AD's genetic underpinnings is vital for therapeutic advancements.

Conclusions:

  • The study highlights the critical juncture for advancing biomarker research in AD.
  • Developing disease-modifying strategies for AD is a timely and necessary goal.
  • Intervening early in AD may prevent the progression to allergic asthma, a concept known as the 'atopic march'.